perimenopause
perimenopause
The conversation happened in a corridor, not a meeting room. A Chief Operating Officer, forty-seven years old, pulled me aside after a session on cognitive performance and said something I have heard, in different forms, from dozens of senior women since: "I think something is wrong with my brain. I can't tell if it's stress or something else.
And I can't ask anyone because I don't know how to have the conversation without it sounding like I'm saying I can't do my job."
She was not describing a crisis. She was describing perimenopause — the hormonal transition that typically begins in the mid-forties and can last anywhere from four to twelve years before the menopause itself. And she was right that she could not easily have the conversation.
Not because the experience was unusual — it affects every woman who lives long enough — but because the professional context had made it unspeakable.
This is a problem with consequences that extend well beyond the individual. The women most likely to be in perimenopause are the women most likely to be in senior leadership roles. The cognitive and neurological changes associated with this transition are real, measurable, and significantly under-researched.
And the absence of accurate information means that women are navigating a major biological transition without a map, often misattributing the symptoms to stress, burnout, or — most damagingly — declining capability.
The neurological effects of perimenopause are not well understood by most people, including many of the women experiencing them. The dominant cultural narrative frames perimenopause as a reproductive event — the winding down of fertility — with some associated physical symptoms. The cognitive dimension is rarely discussed with the specificity it deserves.
Oestrogen is not primarily a reproductive hormone. It is a neuroactive steroid that has profound effects on brain function. Oestrogen receptors are distributed throughout the brain, with particularly high concentrations in the hippocampus, the prefrontal cortex, and the amygdala — the three regions most directly implicated in memory, executive function, and emotional regulation.
When oestrogen levels fluctuate during perimenopause, the effects are not confined to the reproductive system. They are felt across the entire neural architecture that supports cognitive performance.
Research by Pauline Maki at the University of Illinois at Chicago, one of the leading researchers on cognition and the menopause transition, has documented specific patterns of cognitive change during perimenopause.
Her longitudinal studies, following women through the transition, found that verbal memory — the ability to recall words, names, and verbal information — shows measurable decline during the perimenopausal period, with recovery in the post-menopausal phase. The decline is not permanent. But it is real, and it is most pronounced during the transition itself.
Research by Roberta Brinton at the University of Southern California has provided a neurological explanation for this pattern.
Her work on the "critical window hypothesis" proposes that the brain has a period of heightened vulnerability during the hormonal fluctuations of perimenopause — a window during which the neural systems that depend on oestrogen for their optimal function are in a state of adaptation. The brain is not failing. It is reorganising.
But the reorganisation has a cost, and that cost is most visible in the cognitive domains that depend on the hippocampus and prefrontal cortex.
The cognitive changes associated with perimenopause are not uniform. They cluster around specific domains, and understanding which domains are affected — and why — is essential to managing the transition intelligently.
The first and most commonly reported change is verbal memory. Women in perimenopause frequently report difficulty with word retrieval — the experience of knowing a word but being unable to access it, or of losing names that were previously automatic. Research by Maki and colleagues has confirmed that this is not imaginary.
Verbal memory performance on standardised tests declines measurably during the perimenopausal transition, correlating with the degree of hormonal fluctuation rather than chronological age.
The second domain is attentional control — the ability to sustain focused attention on a task and resist distraction. Research by Miriam Weber at the University of Rochester has found that women in perimenopause show reduced performance on tasks requiring sustained attention, particularly under conditions of sleep disruption.
This is significant because sleep disruption is one of the most common symptoms of perimenopause, and the relationship between sleep quality and attentional control is well-established.
The third domain is processing speed — the rate at which the brain can execute cognitive operations. Research using neuroimaging has shown that the white matter tracts that support rapid neural communication are sensitive to oestrogen levels, and that the fluctuations of perimenopause are associated with measurable changes in processing speed on timed cognitive tasks.
The fourth domain, and perhaps the most consequential for senior leaders, is working memory under load. Research by Weber and colleagues has shown that working memory — the ability to hold and manipulate information in real time while managing competing demands — is particularly sensitive to the hormonal fluctuations of perimenopause.
The effect is most pronounced under conditions of high cognitive demand, which is precisely the condition that defines senior leadership.
Sleep disruption is not merely a symptom of perimenopause. It is a mechanism through which the cognitive effects of the hormonal transition are amplified.
The relationship between oestrogen, progesterone, and sleep architecture is well-documented. Oestrogen supports the regulation of body temperature, and the vasomotor symptoms of perimenopause — hot flushes and night sweats — directly disrupt sleep continuity.
Progesterone has sedative properties and supports slow-wave sleep; as progesterone levels decline during perimenopause, the quality of deep sleep deteriorates.
Research by Matthew Walker at the University of California, Berkeley, has established that slow-wave sleep is the phase during which the brain clears the metabolic waste products of cognitive activity, consolidates memories from the previous day, and restores the prefrontal cortex's regulatory capacity. When slow-wave sleep is disrupted, these processes are incomplete.
The cognitive consequences — reduced working memory, impaired emotional regulation, reduced attentional control — are the same consequences produced by the direct neurological effects of oestrogen fluctuation.
This means that the cognitive changes of perimenopause are not simply a direct effect of hormonal change. They are the combined effect of hormonal change and the sleep disruption that hormonal change produces — a double mechanism that compounds the impact on cognitive performance.
For senior women leaders, who are already operating in environments that generate high cognitive load and limited recovery time, this compounding effect is particularly significant.
The research on interventions for perimenopausal cognitive symptoms is more nuanced than the public conversation suggests. Hormone replacement therapy (HRT) has been the subject of significant controversy, and the evidence on its cognitive effects is genuinely complex.
The critical window hypothesis proposed by Brinton suggests that the timing of HRT initiation matters enormously. Studies that have found cognitive benefits from HRT have generally involved women who began treatment during the perimenopausal transition — within the critical window.
Studies that have found no benefit, or harm, have generally involved women who began treatment significantly after the menopause. The brain's oestrogen receptors appear to require a certain level of hormonal activity to remain responsive; once that responsiveness is lost, exogenous oestrogen may not restore it.
The clinical implications of this research are significant, but they require a conversation with a specialist who is current on the evidence — which is evolving rapidly.
The Women's Health Initiative study, which generated much of the concern about HRT in the early 2000s, used a specific formulation (conjugated equine oestrogen plus medroxyprogesterone acetate) in a specific population (postmenopausal women with an average age of sixty-three).
Its findings are not straightforwardly generalisable to perimenopausal women in their forties using different formulations.
Beyond HRT, the research on non-pharmacological interventions is encouraging. Exercise has the strongest evidence base. Research by Kirk Erickson at the University of Pittsburgh has shown that aerobic exercise increases hippocampal volume and improves memory performance in women across the menopausal transition.
The mechanism is well-understood: exercise increases brain-derived neurotrophic factor (BDNF), which supports the growth and maintenance of neurons, and is particularly beneficial for the hippocampal neurons that are most vulnerable to oestrogen fluctuation.
Sleep optimisation — addressing the vasomotor symptoms that disrupt sleep continuity — has measurable cognitive benefits independent of any direct effect on hormonal levels. Cognitive behavioural therapy for insomnia (CBT-I) has been shown to be effective for perimenopausal sleep disruption and produces improvements in daytime cognitive performance.
The most significant barrier to managing perimenopausal cognitive changes effectively is not biological. It is organisational.
Research by Myra Hunter at King's College London on menopause in the workplace has found that the majority of women in senior roles do not disclose perimenopausal symptoms to their employers, and that the primary reason is fear of professional consequences — specifically, fear of being perceived as less capable or less committed. This is not an irrational fear.
The same research found that when women did disclose, the responses from managers were frequently unhelpful or dismissive.
The consequence of this silence is that women are managing a significant biological transition without workplace accommodation, without adjusted expectations during the period of maximum cognitive disruption, and without the information they need to understand what is happening and why.
The COO in the corridor was not unusual in her experience. She was unusual only in having the opportunity to name it — and in having a context in which naming it was safe.
The most important reframe for senior women navigating perimenopause is this: the cognitive changes associated with this transition are not evidence of declining capability. They are evidence of a biological system in transition, with a well-documented trajectory and a recovery phase on the other side.
Research by Maki and colleagues has shown that the verbal memory decline observed during perimenopause reverses in the post-menopausal phase. The brain adapts to its new hormonal environment.
The cognitive performance of post-menopausal women, when measured against their pre-menopausal baseline, shows recovery in most domains — and in some domains, including certain aspects of emotional processing and social cognition, shows improvement.
The transition is not the destination. It is a passage through a period of neurological reorganisation, with a cost that is real but time-limited.
What determines how well a woman navigates that passage is not primarily biological. It is the quality of the information she has, the accuracy of her self-assessment, the adequacy of her recovery conditions, and the degree to which her professional environment accommodates the reality of what she is managing.
The Exceptional Performance for Women in Leadership programme is built around precisely this understanding.
It provides the neurological framework for understanding what is happening during the transition, the evidence-based interventions that have the strongest research support, and the assessment tools that allow women to track their own cognitive baseline through the transition — so they know what they are working with, rather than guessing.
The COO in the corridor did not need to be told that something was wrong with her brain. She needed to be told that her brain was doing exactly what brains do during a major hormonal transition, that the experience was temporary, that the research on recovery was genuinely encouraging, and that there were specific, evidence-based things she could do about it.
That conversation changed her relationship with what she was experiencing. Not because it made the symptoms disappear. Because it gave her accurate information in place of the silence that had left her filling the gap with fear.
Core and Premium programmes with personalised expert reports and AI coaching.
View Programme Options →